Cancer treatment just got a little bit more personalized thanks to Odimma Therapeutics. Led by founder Jessica Matta, this French-based pharmaceutical manufacturing startup has raised $2.2 million in seed funding from Bpifrance to develop its innovative immunotherapy platform. With each tumor being genetically unique and having specific tumor markers, Odimma's next-generation precision immunotherapy platform is designed to induce a powerful cellular immune response against specific tumor markers, representing a game-changer in the field of immune oncology. 

By harnessing the patient's immune system to recognize specific markers displayed by tumor cells, Odimma's approach opens new avenues to fight the most hard-to-treat cancers. Their proprietary DNA-based personalized immunotherapy formulation, ODI-2001, combines three specific immune players to act in synergy on the immune system, inducing and amplifying an immune response against what makes each tumor unique. With a favorable economic profile and the use of synthetic DNA, Odimma is poised to offer innovative and personalized therapeutic options that will revolutionize cancer treatment.